Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aurinia Pharmaceuticals (AUPH), BioCryst (BCRX) and Flexion Therapeutics (FLXN).
Aurinia Pharmaceuticals (AUPH)
In a report issued on March 6, Douglas Miehm from RBC Capital maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $20.00. The company’s shares closed last Monday at $15.29.
According to TipRanks.com, Miehm is a 1-star analyst with an average return of -4.6% and a 42.3% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Medical Facilities, and CRH Medical.
Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $27.20, representing a 75.8% upside. In a report issued on March 5, Oppenheimer also maintained a Buy rating on the stock with a $22.00 price target.
See today’s analyst top recommended stocks >>
BioCryst (BCRX)
In a report issued on March 5, Brian Abrahams from RBC Capital maintained a Hold rating on BioCryst, with a price target of $4.00. The company’s shares closed last Monday at $3.62.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 11.1% and a 53.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Proteostasis Therapeutics, and Intra-Cellular Therapies.
BioCryst has an analyst consensus of Moderate Buy, with a price target consensus of $7.33, representing a 71.3% upside. In a report issued on March 5, Needham also maintained a Hold rating on the stock.
Flexion Therapeutics (FLXN)
RBC Capital analyst Randall Stanicky maintained a Buy rating on Flexion Therapeutics on March 4 and set a price target of $22.00. The company’s shares closed last Monday at $13.07.
According to TipRanks.com, Stanicky is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -14.7% and a 22.0% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Osmotica Pharmaceuticals, and Pacira Pharmaceuticals.
Flexion Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $28.88.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
